Cargando…

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy

SIMPLE SUMMARY: The efficacy and safety of the BNT126b2 vaccine against SARS-CoV-2 has not been thoroughly studied in cancer patients treated with immunotherapy. This research aims to investigate the efficacy and safety of the vaccine in patients with melanoma under immunotherapy; at the same time,...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamantopoulos, Panagiotis T., Kontandreopoulou, Christina-Nefeli, Gkoufa, Aikaterini, Solomou, Elena, Anastasopoulou, Amalia, Palli, Eleni, Kouzis, Panagiotis, Bouros, Spyros, Samarkos, Mihalis, Magiorkinis, Gkikas, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367332/
https://www.ncbi.nlm.nih.gov/pubmed/35954454
http://dx.doi.org/10.3390/cancers14153791
_version_ 1784765773043990528
author Diamantopoulos, Panagiotis T.
Kontandreopoulou, Christina-Nefeli
Gkoufa, Aikaterini
Solomou, Elena
Anastasopoulou, Amalia
Palli, Eleni
Kouzis, Panagiotis
Bouros, Spyros
Samarkos, Mihalis
Magiorkinis, Gkikas
Gogas, Helen
author_facet Diamantopoulos, Panagiotis T.
Kontandreopoulou, Christina-Nefeli
Gkoufa, Aikaterini
Solomou, Elena
Anastasopoulou, Amalia
Palli, Eleni
Kouzis, Panagiotis
Bouros, Spyros
Samarkos, Mihalis
Magiorkinis, Gkikas
Gogas, Helen
author_sort Diamantopoulos, Panagiotis T.
collection PubMed
description SIMPLE SUMMARY: The efficacy and safety of the BNT126b2 vaccine against SARS-CoV-2 has not been thoroughly studied in cancer patients treated with immunotherapy. This research aims to investigate the efficacy and safety of the vaccine in patients with melanoma under immunotherapy; at the same time, through the immunophenotyping of T cells and myeloid cells of the peripheral blood, it will be possible to look for changes in the subpopulations of such cells after vaccinations. The results of the study help establish the efficacy and safety of the vaccine in this population, especially since a theoretical concern exists about the vaccine triggering irAEs. ABSTRACT: The BNT162b2 vaccine against SARS-CoV-2 has a proven efficacy and a favorable safety profile. In cancer patients under immunotherapy in the form of immune-checkpoint inhibitors (ICIs), the efficacy of the vaccine has not been thoroughly studied, while a theoretical concern has also been raised about triggering immune-related adverse events (irAEs) by the vaccine. We conducted a prospective, non-interventional study on the immunogenicity and safety of the BNT162b2 vaccine in patients with advanced or metastatic melanoma treated with ICIs. Blood samples were obtained 0–4 days before the first dose and 12–21 days after the second dose of the vaccine for the quantification of the SARS-CoV-2 anti-spike antibody using an ELISA and immunophenotyping of the T and myeloid cell subpopulations. The active recording of AEs for a two-month period was conducted. Forty patients were included in the study. All but one (97.3%) achieved seroconversion after two doses of the vaccine and no correlations of the antibody titers with any of the studied parameters (age, gender, stage and duration of the disease, type of ICI, previous treatment, etc.) were found. Moreover, no differences in the subpopulations of the T cells (including the T-regulatory cells) or the myeloid cells were found pre- and post-vaccination. All AEs were low-grade, while one case of arthritis exacerbation was noted. The seroconversion rate in the studied population was high and was comparable to that of healthy subjects, while no major safety issues were raised during the safety follow-up. Finally, no derangements in the subpopulations of T cells or myeloid cells were noted. This is the first study focusing on the immunogenicity, safety, and effect of anti-SARS-CoV-2 vaccines on the blood-cell immunophenotype status of patients with melanoma treated with ICIs.
format Online
Article
Text
id pubmed-9367332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93673322022-08-12 Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy Diamantopoulos, Panagiotis T. Kontandreopoulou, Christina-Nefeli Gkoufa, Aikaterini Solomou, Elena Anastasopoulou, Amalia Palli, Eleni Kouzis, Panagiotis Bouros, Spyros Samarkos, Mihalis Magiorkinis, Gkikas Gogas, Helen Cancers (Basel) Article SIMPLE SUMMARY: The efficacy and safety of the BNT126b2 vaccine against SARS-CoV-2 has not been thoroughly studied in cancer patients treated with immunotherapy. This research aims to investigate the efficacy and safety of the vaccine in patients with melanoma under immunotherapy; at the same time, through the immunophenotyping of T cells and myeloid cells of the peripheral blood, it will be possible to look for changes in the subpopulations of such cells after vaccinations. The results of the study help establish the efficacy and safety of the vaccine in this population, especially since a theoretical concern exists about the vaccine triggering irAEs. ABSTRACT: The BNT162b2 vaccine against SARS-CoV-2 has a proven efficacy and a favorable safety profile. In cancer patients under immunotherapy in the form of immune-checkpoint inhibitors (ICIs), the efficacy of the vaccine has not been thoroughly studied, while a theoretical concern has also been raised about triggering immune-related adverse events (irAEs) by the vaccine. We conducted a prospective, non-interventional study on the immunogenicity and safety of the BNT162b2 vaccine in patients with advanced or metastatic melanoma treated with ICIs. Blood samples were obtained 0–4 days before the first dose and 12–21 days after the second dose of the vaccine for the quantification of the SARS-CoV-2 anti-spike antibody using an ELISA and immunophenotyping of the T and myeloid cell subpopulations. The active recording of AEs for a two-month period was conducted. Forty patients were included in the study. All but one (97.3%) achieved seroconversion after two doses of the vaccine and no correlations of the antibody titers with any of the studied parameters (age, gender, stage and duration of the disease, type of ICI, previous treatment, etc.) were found. Moreover, no differences in the subpopulations of the T cells (including the T-regulatory cells) or the myeloid cells were found pre- and post-vaccination. All AEs were low-grade, while one case of arthritis exacerbation was noted. The seroconversion rate in the studied population was high and was comparable to that of healthy subjects, while no major safety issues were raised during the safety follow-up. Finally, no derangements in the subpopulations of T cells or myeloid cells were noted. This is the first study focusing on the immunogenicity, safety, and effect of anti-SARS-CoV-2 vaccines on the blood-cell immunophenotype status of patients with melanoma treated with ICIs. MDPI 2022-08-04 /pmc/articles/PMC9367332/ /pubmed/35954454 http://dx.doi.org/10.3390/cancers14153791 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Diamantopoulos, Panagiotis T.
Kontandreopoulou, Christina-Nefeli
Gkoufa, Aikaterini
Solomou, Elena
Anastasopoulou, Amalia
Palli, Eleni
Kouzis, Panagiotis
Bouros, Spyros
Samarkos, Mihalis
Magiorkinis, Gkikas
Gogas, Helen
Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title_full Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title_fullStr Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title_full_unstemmed Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title_short Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
title_sort immunogenicity and safety of the bnt162b2 mrna covid-19 vaccine in patients with melanoma treated with immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367332/
https://www.ncbi.nlm.nih.gov/pubmed/35954454
http://dx.doi.org/10.3390/cancers14153791
work_keys_str_mv AT diamantopoulospanagiotist immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT kontandreopoulouchristinanefeli immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT gkoufaaikaterini immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT solomouelena immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT anastasopoulouamalia immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT pallieleni immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT kouzispanagiotis immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT bourosspyros immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT samarkosmihalis immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT magiorkinisgkikas immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy
AT gogashelen immunogenicityandsafetyofthebnt162b2mrnacovid19vaccineinpatientswithmelanomatreatedwithimmunotherapy